Abstract:We read with interest the article by Faye et al1Faye A.S. et al.Clin Gastroenterol Hepatol. 2020; 18: 1133-1141Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar evaluating the risk factors associated with readmission to the hospital for venous thromboembolism (VTE) among patients with inflammatory bowel disease (IBD). The author found that readmission with VTE is associated with Clostridium difficile infection and discharge to a skilled nursing facility, intermediate care facility, or with home health services. Because their findings are important to current clinical practice, several questions deserve attention. First, the etiology of VTE in IBD is multifactorial, but this study only mentions some factors, such as tobacco use, gender, malignancy, history of VTE, older age, comorbidities, and surgical treatment. VTE is associated with variations of multiple genes that interact with lifestyle or other environmental factors. There are many common genetic variants that have been found to affect the risk of thrombosis, such as methylenetetrahydrofolate reductase gene mutation (MTHFR), plasminogen activator inhibitor type 1 (PAI-1) gene mutation, factor V Leiden, factor II, and factor XIII.2Koutroubakis I.E. et al.Inflamm Bowel Dis. 2007; 13: 410-415Crossref PubMed Scopus (40) Google Scholar, 3Saibeni S. et al.Dig Liver Dis. 2003; 35: 32-36Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar The prevalence of these factors is different between IBD patients with VTE and IBD patients without VTE2Koutroubakis I.E. et al.Inflamm Bowel Dis. 2007; 13: 410-415Crossref PubMed Scopus (40) Google Scholar; hence, the risk of VTE in patients with IBD with these genetic variants is higher. However, this study did not examine these genetic variants. Second, inflammation has an important role in the pathophysiology of VTE because repetitive episodes of endothelial damage can lead to a sustained prothrombotic state. Some studies have reported a substantially higher risk of VTE during periods of active disease as compared with periods of remission.4Grainge M.J. et al.Lancet. 2010; 375: 657-663Abstract Full Text Full Text PDF PubMed Scopus (424) Google Scholar Disease activity, which can act as potential confounding factor, was not assessed in this study. Third, some drugs can affect the risk of VTE in IBD. For example, corticosteroids can independently contribute to the increased risk of VTE in patients with IBD. The use of corticosteroids not only increases platelet function, but it is an independent risk factor for VTE and induces both hypercoagulability and a hypofibrinolytic state.5Huerta C. et al.Arch Intern Med. 2007; 167: 935-943Crossref PubMed Scopus (293) Google Scholar However, some studies found that patients with IBD treated with corticosteroids are more likely to moderate to severe inflammatory disease.6Higgins P.D. et al.Clin Gastroenterol Hepatol. 2014;13:316-321; Google Scholar Therefore, it is impossible to separate the direct impact of corticosteroids from its indirect impact on VTE through its effects on disease activity in patients with IBD. Because most patients with IBD would have tapered off steroids within a few months, the observation of VTE occurring throughout the follow-up period in this group cannot be attributed entirely to the effects of corticosteroids. On the contrary, infliximab can independently contribute to the decreased risk of VTE in patients with IBD. There is evidence that infliximab decreases the coagulation biomarkers and activates the fibrinolytic system.7Ingegnoli F. et al.J Autoimmun. 2008; 31: 175-179Crossref PubMed Scopus (94) Google Scholar However, some studies found that infliximab therapy achieves better overall disease control than corticosteroid-based treatment in IBD,8Hanauer S.B. et al.Lancet. 2002; 359 (1541–1529)Abstract Full Text Full Text PDF PubMed Scopus (3429) Google Scholar which may have largely dictated the observed associations. The current study did not mention the treatment for patients with IBD. In conclusion, the risk factors of VTE in patients with IBD are worth further discussion. Future prospective population-based studies should stratify patients with IBD according to genetic variants, disease activity, and the medications to assess risk and risk factors associated with of VTE in patients with IBD. Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and HepatologyVol. 18Issue 5PreviewPatients with inflammatory bowel diseases (IBDs) have a high risk of venous thromboembolism (VTE). We assessed the timing and risk factors associated with readmission to the hospital for VTE among patients with IBD. Full-Text PDF ReplyClinical Gastroenterology and HepatologyVol. 18Issue 13PreviewWe thank Cong Dai et al for their comments on this topic, and for their interest in our article. Regarding genetics, we agree that this may be an important factor to consider when determining which inflammatory bowel disease (IBD) patients are at highest risk for after discharge thrombotic events. The prevalence of these polymorphisms appear to be similar in IBD and non-IBD patients,1–3 and, as such, genetic data often only are collected after an initial thrombotic event. The Nationwide Readmissions Database does not have genetic data on individual patients, but records the history of prior venous thromboembolism (VTE), which can be considered as a surrogate for this risk. Full-Text PDF

Incidence and impact of venous thromboembolism in hospitalized patients with Crohn's disease

IDDF2018-ABS-0209 Venous Thromboembolism in Patients with Inflammatory Bowel Disease in China: Investigations into Incidence and Risk Factors

Incidence and Risk Factors for Venous Thrombosis among Patients with Inflammatory Bowel Disease in China: a Multicenter Retrospective Study

Acute Venous Thromboembolism Risk in Patients with Inflammatory Bowel Diseases.

P1029 Prevalance and risk factors of thromboembolism in Inflammatory Bowel Disease

High Incidence and Morbidity of Clostridium Difficile Infection among Hospitalized Patients with Inflammatory Bowel Disease: A Prospective Observational Cohort Study

P1089 Disease characteristics at time of diagnosis of adult onset inflammatory bowel disease and the risk of venous thromboembolism in the modern era – A Swedish nationwide cohort study 2007-2021

Risk assessment of venous thromboembolism in inflammatory bowel disease by inherited risk in a population-based incident cohort

Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting

P1137 Long-term trend of cumulative incidence of venous thromboembolism in Korean patients with inflammatory bowel disease: A nationwide population-based cohort study

Impact of connective tissue diseases on inpatient outcomes in gastrointestinal bleeding: insights from a national database analysis

P1151 Incidence and risk factors of thromboembolic events in Pediatric-Onset Inflammatory Bowel Disease: a population-based study

FP2.6 - Opportunities for Improvement in Venous Thromboprophylaxis (VTE) of High-Risk Patients Hospitalized for Inflammatory Bowel Disease (IBD) Related Bowel Resection

Timing and Location of Venous Thromboembolisms After Surgery for Inflammatory Bowel Disease

Long-term risk of venous thromboembolism among patients with gastrointestinal non-neoplastic and neoplastic diseases: A prospective cohort study of 484 211 individuals

The prevalence and risk factors of venous thromboembolism in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease

Prevalence and risk factors of postoperative venous thromboembolism in Cushing’s disease and establishment of a risk assessment model

Tu1732 TWO-DIMENSIONAL SHEAR WAVE ELASTOGRAPHY FOR PREDICTING HIGH-RISK VARICES IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE

754 Venous Thromboembolism Incidence and Risk Factors in Burn Patients

Incidence and risk factors for thromboembolic events in pediatric-onset inflammatory bowel disease: A French population-based study

Controversies in Venous Thromboembolism Risk Assessment in Inflammatory Bowel Disease: A Narrative Review